COMPATIBILITY OF THE GROWTH PROMOTER SODI UM-SALINOMYCIN AND LINCOMYCIN AS WELL AS LINCOMYCIN SPECTINOMYCIN IN SWINE

In a study on 144 healthy pigs, the tolerability of the simultaneous i n-feed-administration of the performance enhancer Salinomycin-sodium ( SAL) and the therapeutics Lincomycin (ALB) and Lincomycin/Spectinomyci n (LIN) resp. was analysed. A total of 6 trial groups were investigate d (zero control, SAL, ALB, LIN, SAL + ALB, SAL + LIN). SAL was applied over the whole trial (20 weeks, from 10 to approx. 100 kg of live wei ght) at 60 (week 1 to 12) and 30 mg/kg of feed resp. (week 13 to 20). ALB and LIN were fed for 3 trial periods of 21 days each (week 1 - 3/7 - 9/13 - 15) at a dosage of 110 mg/kg of feed. Clinical symptoms of a n incompatibility reaction in groups of combined application were not detectable at any time. Results from the whole trial period outlined a positive additive effect in the combination groups (SAL + ALB; SAL LIN) in growth rate and feed conversion compared to SAL alone. This wa s evident particularly in trial period II where highest intake per hea d and day of SAL and ALB or LIN was achieved. Weight gain was improved by 8.7-9 percent, feed conversion by 5.9-6.3 percent. Salocin(R) as a performance enhancer and the in-feed-therapeutics Albiotic(R) and Lin cospectin(R) revealed to be compatible without restrictions in practic al dosages.